Ovarian hyperstimulation syndrome. Hyperstimulation of ovaries
Conditions
Interventions
Intervention 1: Intervention group: Hydrocortisone acts as an anti-inflammatory drug and, based on previous studies, this drug has been used for other inflammatory diseases such as rheumatoid arthriti
Sponsors
Islamic Azad University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Patients with polycystic ovary syndrome (PCOS) Age 18 to 40 years old Antral follicle count (AFC) above 20 AMH>3.36 ng/ml BMI) <30 kg/m2) Ovarian stimulation treatment cycles with antagonist only
Exclusion criteria
Exclusion criteria: Endometriosis Decreased ovarian reserve Chromosomal abnormality History of sensitivity to dopamine blocking drugs or cabergoline or hydrocortisone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence or absence of ascites fluid within the abdomen/Presence or absence of pain in the abdominal area. Timepoint: Three and eight days after the pickup, clinical symptoms, laboratory tests, and ultrasound are performed to check for OHSS. Method of measurement: Clinical, laboratory and ultrasound signs. | — |
Secondary
| Measure | Time frame |
|---|---|
| Decreased expression of prostaglandin E2 and angiotensin II genes in serum after drug intervention/Reduction in IL1 and IL8 protein levels in follicular fluid and plasma before and after drug intervention. Timepoint: All patients are asked to take the prescribed medication for 10 days at the same time as starting the trigger (GNRH agonist). Method of measurement: Real-time PCR/Eliza. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShima Monavarian
Islamic Azad University
Outcome results
None listed